Radical Retropubic Prostatectomy and Postoperative Adjuvant Radiation for Pathological Stage C (PCN0) Prostate Cancer from 1976 to 1989: Intermediate Findings

No AccessJournal of Urology1 May 1993Radical Retropubic Prostatectomy and Postoperative Adjuvant Radiation for Pathological Stage C (PCN0) Prostate Cancer from 1976 to 1989: Intermediate Findings John A. Freeman, Gary Lieskovsky, Donald W. Cook, Zbigniew Petrovich, Suchiu Chen, Susan Groshen, and Donald G. Skinner John A. FreemanJohn A. Freeman More articles by this author , Gary LieskovskyGary Lieskovsky More articles by this author , Donald W. CookDonald W. Cook More articles by this author , Zbigniew PetrovichZbigniew Petrovich More articles by this author , Suchiu ChenSuchiu Chen More articles by this author , Susan GroshenSusan Groshen More articles by this author , and Donald G. SkinnerDonald G. Skinner More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)36288-2AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Between 1976 and 1989, 114 patients undergoing radical retropubic prostatectomy and bilateral pelvic lymph node dissection for prostatic adenocarcinoma were found to have stage PcNO lesions. Postoperative adjuvant radiation therapy without hormonal treatment was given to 95 of these patients (83%): 26 (27%) with stage Cl, 37 (39%) with stage C2 and 32 (34%) with stage C3 disease. The median radiation dose was 45Gy. given at 180cGy. daily. Median followup was 4.4 years (range 1.4 to 13.3). The overall 5 and 10-year actuarial survival rates for the patients were 94% and 70%, respectively. Disease-specific 5 and 10-year actuarial survival rates were 99% and 78%, respectively. At 5 and 10 years the chance of clinical recurrence was estimated as 6% and 13%, respectively, and the chance of recurrence (clinical or indicated by prostate specific antigen levels) was estimated to be 34% and 46%, respectively. Patients with high Gleason scores (8 to 10) and seminal vesicle involvement (stage C3) fared worst. There were 5 patients with clinical distant metastases, 1 with a clinical local recurrence and 1 with both conditions. Detectable elevation of prostate specific antigen without clinically evident recurrence was noted in 25 patients. Radiation therapy was well tolerated with minimal morbidity. Disease-specific survival and survival without clinical recurrence were improved over historical control in patients with stage PcNO prostate cancer treated by radical prostatectomy alone. These data support a role for adjuvant radiation therapy in stage PcNO prostate adenocarcinoma following radical prostatectomy. © 1993 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByKOPPIE T, GROSSFELD G, NUDELL D, WEINBERG V and CARROLL P (2018) IS ANASTOMOTIC BIOPSY NECESSARY BEFORE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY?Journal of Urology, VOL. 166, NO. 1, (111-115), Online publication date: 1-Jul-2001.GROSSFELD G, TIGRANI V, NUDELL D, ROACH M, WEINBERG V, PRESTI J, SMALL E and CARROLL P (2018) MANAGEMENT OF A POSITIVE SURGICAL MARGIN AFTER RADICAL PROSTATECTOMY: DECISION ANALYSISJournal of Urology, VOL. 164, NO. 1, (93-100), Online publication date: 1-Jul-2000.LEIBOVICH B, ENGEN D, PATTERSON D, PISANSKY T, ALEXANDER E, BLUTE M, BERGSTRALH E and ZINCKE H (2018) BENEFIT OF ADJUVANT RADIATION THERAPY FOR LOCALIZED PROSTATE CANCER WITH A POSITIVE SURGICAL MARGINJournal of Urology, VOL. 163, NO. 4, (1178-1182), Online publication date: 1-Apr-2000.Syndikus I, Pickles T, Kostashuk E and Sullivan L (2018) Postoperative Radiotherapy for Stage pT3 Carcinoma of the Prostate: Improved Local ControlJournal of Urology, VOL. 155, NO. 6, (1983-1986), Online publication date: 1-Jun-1996.Formenti S, Lieskovsky G, Simoneau A, Skinner D, Groshen S, Chen S and Petrovich Z (2018) Impact of Moderate Dose of Postoperative Radiation on Urinary Continence and Potency in Patients with Prostate Cancer Treated with Nerve Sparing ProstatectomyJournal of Urology, VOL. 155, NO. 2, (616-619), Online publication date: 1-Feb-1996.Freeman J, Esrig D, Grossfeld G, Stein J, Su-Chiu C, Young L, Taylor C, Skinner D, Lieskovsky G and Cote R (2018) Incidence of Occult Lymph Node Metastases in Pathological Stage C (pT3NO) Prostate CancerJournal of Urology, VOL. 154, NO. 2, (474-478), Online publication date: 1-Aug-1995.D'Amico A, Whittington R, Malkowicz S, Schultz D, Schnall M, Tomaszewski J and Wein A (2018) A Multivariate Analysis of Clinical and Pathological Factors that Predict for Prostate Specific Antigen Failure after Radical Prostatectomy for Prostate CancerJournal of Urology, VOL. 154, NO. 1, (131-138), Online publication date: 1-Jul-1995.Zietman A, Shipley W and Coen J (2018) Radical Prostatectomy and Radical Radiation Therapy for Clinical Stages T1 to 2 Adenocarcinoma of the Prostate: New Insights into Outcome from Repeat Biopsy and Prostate Specific Antigen FollowupJournal of Urology, VOL. 152, NO. 5 Part 2, (1806-1812), Online publication date: 1-Nov-1994.Mccarthy J, Catalona W and Hudson M (2018) Effect of Radiation Therapy on Detectable Serum Prostate Specific Antigen Levels Following Radical Prostatectomy: Early Versus Delayed TreatmentJournal of Urology, VOL. 151, NO. 6, (1575-1578), Online publication date: 1-Jun-1994. Volume 149Issue 5 Part 1May 1993Page: 1029-1034 Advertisement Copyright & Permissions© 1993 by The American Urological Association Education and Research, Inc.Keywordsadenocarcinomaprostatic neoplasmsradiotherapyprostatectomyMetricsAuthor Information John A. Freeman More articles by this author Gary Lieskovsky More articles by this author Donald W. Cook More articles by this author Zbigniew Petrovich More articles by this author Suchiu Chen More articles by this author Susan Groshen More articles by this author Donald G. Skinner More articles by this author Expand All Advertisement PDF DownloadLoading ...